Altimmune (ALT) Total Current Liabilities (2010 - 2026)

Altimmune (ALT) has 17 years of Total Current Liabilities data on file, last reported at $11.3 million in Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $11.3 million, up 15.56% year-over-year; the trailing twelve-month figure through Mar 2026 was $11.3 million (up 15.56% YoY), and the FY2025 annual result was $15.0 million, up 43.27% from the prior year.
• Total Current Liabilities fell to $11.3 million in Q1 2026 per ALT's latest filing, from $15.0 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $19.1 million in Q1 2022 and troughed at $8.6 million in Q3 2024.
• A 5-year average of $12.9 million and a median of $12.1 million in 2023 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2022 and 2025: Total Current Liabilities surged 94.67% in 2022, then tumbled 39.16% in 2025.
• A 5-year view of Total Current Liabilities shows it stood at $17.1 million in 2022, then declined by 28.8% to $12.1 million in 2023, then declined by 13.79% to $10.5 million in 2024, then soared by 43.27% to $15.0 million in 2025, then slipped by 24.5% to $11.3 million in 2026.
• Business Quant data shows ALT's Total Current Liabilities at $11.3 million in Q1 2026, $15.0 million in Q4 2025, and $12.6 million in Q3 2025.